Allergan Aktie
WKN: 877437 / ISIN: US0184901025
06.04.2015 15:16:38
|
Icon Bioscience Reports Phase 3 Data For IBI-10090 - Quick Facts
(RTTNews) - Icon Bioscience Inc. announced that Phase 3 data showed significantly positive outcomes for IBI-10090 compared to placebo in treating inflammation associated with cataract surgery. The company reported that the ensuing analysis of data showed IBI-10090 - with regard to both primary and secondary study endpoints - to be safe as well as highly effective.
The Phase 3 study of IBI-10090 was a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial involving 394 patients.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Allergan Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |